Engelsk titel: Targeted treatment of chronic lymphocytic leukaemia
Läs online
Författare:
Niemann, Carsten Utoft
Email: niemann@dadlnet.dk
Språk: Dan
Antal referenser: 30
Dokumenttyp:
Översikt
UI-nummer: 15077403
Sammanfattning
The development of targeted treatment of chronic lymphocytic leukaemia (CLL) is changing the prognostic outlook for CLL patients. The B-cell antigen
receptor pathway is identified as pivotal for CLL pathogenesis and CLL cell proliferation. Inhibition of this pathway by ibrutinib (Bruton’s tyrosin kinase
inhibition) and idelalisib (phosphatidylinositol 3-kinase inhibition) has recently shown impressive clinical results, also for CLL patients with
relapsed/refractory disease and unfavourable prognostic markers. Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising
clinical results.